Asimov And Emergent Biosolutions Announce Cell Line Development Partnership To Advance Novel Antibodies Against Ebola
To support its efforts around health preparedness, Emergent will use Asimov’s CHO Edge System to help develop novel medical countermeasures
Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development, and Emergent Biosolutions, a leading global public health company, today announced a cell line development partnership. The partnership covers two full cell line development campaigns, from vector design and synthesis through the production and shipment of a high-titer research cell bank, for two monoclonal antibodies targeting Ebola.
“We are proud to partner with Emergent as they develop medical countermeasures to strengthen our ability to combat biological threats,” said Alec Nielsen, co-founder and CEO of Asimov. “Emergent has a long history of developing essential medicines, and we look forward to working with their team on this important work.”
Emergent specializes in developing, manufacturing, and delivering medical countermeasures for critical biological threats like anthrax, smallpox, mpox, botulism and Ebola. Emergent aims to develop high-titer cell lines by using Asimov’s CHO Edge System, which combines a GS knock-out CHO host, hyperactive transposase, genetic parts library, and Kernel, Asimov's AI-driven genetic design software.
“Ebola remains one of the most serious health threats, demanding continued innovation and investment in next-generation medical countermeasures,” said Joe Papa, president and CEO of Emergent. “By utilizing Asimov’s AI-native advanced cell line development capabilities in combination with Emergent’s deep expertise in biodefense, we aim to accelerate the development of novel antibody candidates that have the potential to strengthen preparedness and help protect and save lives.”
About Asimov
Asimov’s mission is to advance humanity’s ability to design living systems, enabling biotechnologies with outsized societal benefit. The company is developing a synthetic biology platform – from cells to software – to design and manufacture next-generation therapeutics, including biologics, cell/gene therapies, and RNA through a combination of products, services, and collaborations.
Founded by bioengineers from MIT and Boston University and headquartered in Boston, the company has raised over $200M from top institutional investors including Andreessen Horowitz, CPP Investments, Horizons Ventures, and Fidelity Management & Research Company. For more information, visit www.asimov.com.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. For more information, visit www.emergentbiosolutions.com.
Source: Asimov, Inc.